Ruby Hall Clinic is a prominent hospital in the city of Pune, India. It is a 750-bed hospital facility with a staff of 300 consultants, 650 panel doctors and 1500 paramedical staff and was accredited by National Accreditation Board for Hospitals & Healthcare Providers (NABH).It is a recognized Post Graduate Teaching Hospital for the Students of Maharashtra University of Health Sciences, National Board of Examinations and College of Physicians & Surgeons of Mumbai. Dr. P.K. Grant is the managing trustee of Ruby Hall Clinic.
The rapid adoption of generative Artificial intelligence (AI) tools, particularly large language models, image generators, and analytics platforms, has opened transformative opportunities in the way medical research is conducted, reported, and evaluated. These tools offer substantial advantages in efficiency, analytical capacity, language equity, and evidence synthesis. When used responsibly, they have the potential to democratize scientific publishing and accelerate knowledge generation, particularly in resource-constrained settings. However, realizing this potential requires clear ethical guardrails. At present, no unified guidance exists that enables Indian researchers in diabetology and metabolic medicine to harness AI confidently while safeguarding scientific integrity. The Research Society for the Study of Diabetes in India (RSSDI), functioning as a national academic body, has developed this position statement to enable the responsible and confident adoption of AI tools across the entire arc of medical research and scholarly publication, while maintaining the ethical and professional standards that underpin scientific credibility. This consensus document was developed through a structured review of publicly available AI policies from the International Committee of Medical Journal Editors (ICMJE, January 2024 update), Springer Nature, Elsevier, Wiley, SAGE, Taylor Francis, the Committee on Publication Ethics (COPE), the World Association of Medical Editors (WAME), and the Indian Council of Medical Research (ICMR) Ethical Guidelines for Application of AI in Biomedical Research and Healthcare (2023). Thematic domains were extracted, compared for convergence, and synthesized into a unified framework. Consensus was achieved through iterative review among the authors. This statement establishes seven core ethical principles: human accountability, transparency and disclosure, data integrity and authenticity, ethical study design and execution, patient confidentiality and data privacy, responsible interpretation, and publication ethics. It provides role-specific guidance for authors, editors, and peer reviewers, with explicit delineation of permitted and prohibited AI uses, mandatory disclosure templates, an image policy aligned with international standards, a violations and sanctions framework, and practical checklists for compliance. This position statement offers a pragmatic, evidence-aligned framework that empowers RSSDI members, journal contributors, reviewers, and editors to use AI tools with confidence and integrity. Rather than restricting technological progress, it provides the ethical infrastructure needed for Indian diabetes researchers to lead in the responsible integration of AI into scholarly practice. It is intended as a living document subject to biannual review.
BACKGROUND:Understanding Indian healthcare professionals' (HCPs) perceptions of beta (β)-blockers is critical, given the high burden of hypertension (HTN) and cardiovascular (CV) diseases in the country. MATERIALS AND METHODS:A cross-sectional survey was conducted among 1,000 Indian HCPs, including consulting physicians, cardiologists, and specialists in diabetes/metabolism experienced in managing adult patients across the HTN and CV disease continuum. Conducted between April 2023 and March 2024, the survey employed a 26-item structured questionnaire, developed through literature review and expert consultation, to assess β-blockers utilization patterns, prescribing preferences, and perceived barriers. RESULTS:Responses from 855 HCPs were analyzed. Consulting physicians (431; 50.4%) and cardiologists (342; 40.0%) formed the majority. β-blockers were prescribed to 25-50% of patients with HTN by 489 (57.2%) HCPs. Approximately 429 (50.2%) observed a systolic BP reduction of 10-15 mm Hg, while 465 (54.4%) reported a diastolic BP reduction of 5-10 mm Hg. β-blockers were commonly prescribed for heart failure (381; 44.6%), postmyocardial infarction (214; 25%), and chronic coronary syndrome (309; 36.1%). Metoprolol was the preferred BB in 75% of HTN, post-MI, chronic coronary syndrome (CCS), and AF cases, and in 66.2% for HF management. CONCLUSION:This survey highlights real-world prescribing patterns and perceptions of β-blockers in India, with metoprolol emerging as the most preferred agent across multiple CV indications, reflecting its strong clinical acceptance and perceived efficacy.
Although inappropriate therapy has been consistently associated with adverse outcomes, the magnitude and consistency of the benefit associated with appropriate empiric therapy in critically ill patients remain uncertain. We aimed to quantify the prevalence of appropriate empiric antimicrobial therapy and evaluate its association with outcomes and antimicrobial exposure in a large international ICU cohort. This predefined sub-analysis of the DIANA study included adult ICU patients receiving empirical antimicrobials for suspected or confirmed bacterial infection. Only patients with microbiologically confirmed infections were analyzed, and therapy was classified as appropriate if at least one agent demonstrated in vitro activity against the identified pathogen. Associations with 28-day mortality and antimicrobial-free days were assessed using multivariable logistic and Cox regression models. Pre-specified interaction analyses explored effect modification by disease severity and diagnostic certainty. Of 845 patients with microbiologically confirmed infections, 87.7
Background Acquired aplastic anemia (AA) is an immune-mediated hematopoietic disorder. It is characterized by pancytopenia and hypocellular bone marrow. The first-line treatment approach to AA includes immunosuppressive treatment (IST) using the combination of antithymocyte globulin (ATG) and cyclosporine A. Those patients who do not respond to this first-line treatment or have refractory disease succumb to bleeding or infections within five years following their diagnosis even after IST. Romiplostim, a thrombopoietin (TPO) receptor antagonist, promotes trilineage hematopoiesis in patients with AA. A retrospective study assessed the safety and effectiveness of romiplostim, as monotherapy among patients with refractory AA in Indian settings. Methods The case record forms of patients diagnosed with refractory AA and receiving treatment with weekly doses of 250 mg romiplostim and concomitant medications were reviewed at Yashoda Hematology Clinic, India. The primary outcome was to evaluate the increase in platelet count/percentage and the safety of romiplostim in these patients. The secondary outcomes were a change in total leucocyte count (TLC) and hemoglobin (Hb) levels from baseline after romiplostim therapy. Results Data from 28 patients diagnosed with AA and having received romiplostim subcutaneously in a dose of 250 mg weekly were analyzed. There was a significant improvement in platelet count which increased by 0.064 × 109/L units (95% CI: 0.021-0.107) at a 100-day interval from the initial measurement. The TLCs also increased by 0.022 × 109/L units (95% CI: 0.002-0.042). The mean Hb levels increased from 7.61 gm/L to 13.38 gm/L (95% CI, p < 0.001). No severe adverse events were reported. Conclusion Romiplostim demonstrated clinically significant outcomes with a favorable safety profile in patients with refractory AA.
How to cite this article: Bhattacharjee A, Pal G, Kundu R. Personalized Parenteral Nutrition-Comparing Apples and Oranges? Indian J Crit Care Med 2026;30(2):179-180.
